title: Transforming growth factor-beta and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma.
abstract: BACKGROUND
  Trichoepithelioma (TE) and basal cell carcinoma (BCC) have many features in common both clinically and histologically. Despite these many similarities TE and BCC represent different biological entities.
  
  
  OBJECTIVE
  Recently, bcl-2 and CD34 have been reported as reliable markers in distinguishing the two types of tumor. Transforming growth factor-beta (TGF-beta), a multifunctional regulator of both cell growth and differentiation, was evaluated in this study.
  
  
  METHODS
  The immunohistochemical expression of TGF-beta was compared with the distribution patterns of bcl-2 and CD34 in five BCCs, five TEs, and seven borderline cases.
  
  
  RESULTS
  All five TEs showed a diffuse cytoplasmic staining of tumor cells for TGF-beta, whereas four of five BCCs were TGF-beta negative. Of the seven equivocal cases of TE/BCC, five tumors demonstrated TGF-beta positivity in combination with negative bcl-2 staining corresponding to TE. The remaining two cases demonstrated the opposite staining pattern, characteristic for BCC.
  
  
  CONCLUSIONS
  The TGF-beta staining pattern appears to be a helpful additional marker together with bcl-2 in differentiating between TE and BCC. The demonstrated staining differences may relate to the distinct origin and biological behavior of the two tumors and may therefore be of value in subsequent patient management.
authors.affiliation: Department of Dermatology, University Hospital Maastricht, The Netherlands.
authors.forename: M E
authors.initials: ME
authors.lastname: Verhaegh
authors.forename: J W
authors.initials: JW
authors.lastname: Arends
authors.forename: I M
authors.initials: IM
authors.lastname: Majoie
authors.forename: R
authors.initials: R
authors.lastname: Hoekzema
authors.forename: H A
authors.initials: HA
authors.lastname: Neumann
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018952:Antigens, CD34 / Q000032:analysis / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D002280:Basal Cell Carcinoma / Q000473:pathology*; D002454:Cell Differentiation; D002455:Cell Division; D004396:Coloring Agents; D003593:Cytoplasm / Q000648:ultrastructure; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D004730:Endothelium, Vascular / Q000473:pathology; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D015603:Keratinocytes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018295:Neoplasms, Basal Cell / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000235:genetics; D015203:Reproducibility of Results; D012878:Skin Neoplasms / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000032:analysis* / Q000235:genetics
chemical_list: D018952:Antigens, CD34; D014408:Biomarkers, Tumor; D004396:Coloring Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D016212:Transforming Growth Factor beta